Our data provide the proof-of-concept that small molecule IRE1α kinase inhibitors like KIRA6 that allosterically reduce RNase-dependent XBP-1 mRNA splicing may lead to a novel approach for treating the excessive inflammation characteristic of CF airways. This evidence concerns the gene XBP1 and cystic fibrosis.